^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)

    i
    Other names: V503, 9vHPV, V-503, V 503
    Associations

    News

    Trials
    Company:
    Chongqing Zhifei, Merck (MSD)
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    7d
    Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023) (clinicaltrials.gov)
    P3, N=6000, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Mar 2028 --> Nov 2029
    Trial completion date
    |
    Gardasil (quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine) • Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)
    1m
    Genotype Distribution of Human Papillomavirus (HPV) Types in Oral Gargle Specimens among Men Living with HIV in Mexico, Brazil, and Puerto Rico: a Cross-Sectional Study. (PubMed, J Infect)
    Oral HPV genotyping in men with HIV reveals distinct oncogenic patterns, underscoring the need to monitor long-term OPSCC risk.
    Clinical • Observational data • Journal
    |
    CD4 (CD4 Molecule)
    |
    Gardasil (quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine) • Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)
    1m
    Immunogenicity of HPV Vaccine in Transplant Recipients. (clinicaltrials.gov)
    P4, N=30, Active, not recruiting, Medical College of Wisconsin | Trial primary completion date: Dec 2025 --> Dec 2028
    Trial primary completion date
    |
    Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)
    1m
    An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen (clinicaltrials.gov)
    P4, N=352, Active, not recruiting, Boston Medical Center | Trial completion date: Jun 2026 --> Oct 2026
    Trial completion date
    |
    Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)
    2ms
    GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose (clinicaltrials.gov)
    P4, N=767, Completed, The University of Texas Medical Branch, Galveston | Active, not recruiting --> Completed
    Trial completion
    |
    Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)
    2ms
    Study on the Safety, Humoral Immune Response, and Memory B Cell Response Characteristics of Sequential 9-Valent HPV Vaccination (clinicaltrials.gov)
    P=N/A, N=360, Not yet recruiting, Jiangsu Province Centers for Disease Control and Prevention
    New trial
    |
    Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)
    2ms
    Human papillomavirus (HPV) seroprevalence, cervical HPV prevalence and cervical lesions in systemic lupus erythematosus (SLE) and immunocompetent women. (PubMed, Lupus Sci Med)
    Our findings underscore the importance of tailored cervical cancer screening and HPV vaccination of SLE women at young age.
    Journal
    |
    PapilloCheck®
    |
    Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)
    2ms
    Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients (clinicaltrials.gov)
    P2, N=51, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)
    2ms
    URVIVE: Developing a First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After HPV Vaccination (clinicaltrials.gov)
    P2, N=50, Recruiting, Universiteit Antwerpen
    Trial initiation date
    |
    TRIP13 (Thyroid Hormone Receptor Interactor 13)
    |
    Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)
    3ms
    URVIVE: Developing a First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After HPV Vaccination (clinicaltrials.gov)
    P2, N=50, Recruiting, Universiteit Antwerpen | Not yet recruiting --> Recruiting
    Enrollment open
    |
    TRIP13 (Thyroid Hormone Receptor Interactor 13)
    |
    Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)
    3ms
    HPV2-2303: Clinical Trial Evaluating Secondary HPV Vaccination After Treatment of High-grade Cervical Lesions (clinicaltrials.gov)
    P2, N=85, Recruiting, Centre Oscar Lambret | Trial completion date: Oct 2031 --> Dec 2031
    Trial completion date
    |
    Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)
    3ms
    A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004) (clinicaltrials.gov)
    P1, N=72, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)